Spectrum Pharmaceuticals Inc. CEO Predicts Reven
Post# of 41
Posted On: 02/13/2013 12:08:54 PM
Spectrum Pharmaceuticals Inc. CEO Predicts Revenue Growth for 2013
The CEO of Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Dr. Rajesh Shrotriya announced high expectations for 2013 and predicted revenue growth for the year. During his presentation at the JPMorgan’s healthcare investor event, Shrotriya announced that his company had recently gone through major changes, and was about to add RenaZorb, a developmental cancer drug, to their catalogue. RenaZorb will be the fourth drug added to the company’s profile, with Fusilev, Folotyn, and Zevalin already going strong.
(0)
(0)Spectrum Pharmaceuticals (SPPI) Stock Research Links
Scroll down for more posts ▼